|
| 37276510 | Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study. | Blood Adv | 2023 |
| 37704508 | The effect of mobilizing large numbers of CD34Â +Â cells (super-mobilizers) on the engraftment and survival in patients undergoing autologous stem cell transplantation. | Transfus Apher Sci | 2023 |
| 36222848 | Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine. | Clin Cancer Res | 2022 |
| 31060979 | Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial. | Lancet Haematol | 2019 |
| 31331399 | Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia. | Clin Epigenetics | 2019 |
| 29211308 | Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia. | Cancer | 2018 |
| 30181421 | Chimeric Antigen Receptor T-Cell Therapy. | J Natl Compr Canc Netw | 2018 |
| 30333627 | Functional genomic landscape of acute myeloid leukaemia. | Nature | 2018 |
| 29556023 | Demethylator phenotypes in acute myeloid leukemia. | Leukemia | 2018 |
| 29616864 | A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia. | Leuk Lymphoma | 2018 |
| 28063304 | Splenic irradiation for splenomegaly: A systematic review. | Cancer Treat Rev | 2017 |
| 28159832 | DNA Hypomethylating Drugs in Cancer Therapy. | Cold Spring Harb Perspect Med | 2017 |
| 28844816 | Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial. | Lancet Oncol | 2017 |
| 28687581 | Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2017 |
| 27956535 | NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017. | J Natl Compr Canc Netw | 2016 |
| 26632076 | Donor Lymphocyte Infusion in Hematologic Malignancies--Good to be Fresh? | Clin Lymphoma Myeloma Leuk | 2016 |
| 26480922 | Healthcare utilization and costs associated with tyrosine kinase inhibitor switching in patients with chronic myeloid leukemia. | Leuk Lymphoma | 2016 |
| 27956542 | Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. | J Natl Compr Canc Netw | 2016 |
| 25870379 | Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms. | J Natl Compr Canc Netw | 2015 |
| 25361806 | Chronic myelogenous leukemia, version 1.2015. | J Natl Compr Canc Netw | 2014 |
| 24225967 | Chronic Myelogenous Leukemia, Version 1.2014. | J Natl Compr Canc Netw | 2013 |
| 22189875 | Spontaneous graft versus host disease occurring in a patient with multiple myeloma after autologous stem cell transplant. | Am J Hematol | 2012 |
| 22461474 | Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia. | Blood | 2012 |
| 20033056 | Dasatinib promotes ATRA-induced differentiation of AML cells. | Leukemia | 2010 |
| 19494839 | Src family kinase gene targets during myeloid differentiation: identification of the EGR-1 gene as a direct target. | Leukemia | 2009 |